RESUMEN
Introducción: La infección por el VIH continúa siendo un problema de salud mundial y nacional. El proceso de descentralización de la atención de estos pacientes hace que cada día sean más los que se atienden en hospitales de nivel secundario. Objetivo: Caracterizar los pacientes con infección por VIH en el municipio Boyeros. Material y Métodos: Se realizó un estudio descriptivo de corte transversal, de las personas con VIH residentes en el municipio Boyeros hasta el 31 de diciembre de 2013. Se analizaron variables demográficas como edad, sexo, escolaridad, ocupación, enfermedades marcadoras de SIDA, tiempo de diagnóstico, conteo de CD4 y tratamiento antirretroviral.Resultados: El mayor número de casos es del sexo masculino, el grupo de edad más afectado es de 20 a 39 años y predomina el nivel escolar preuniversitario (50 por ciento). Existe 30 por ciento de casos desocupados. El 80 por ciento de los casos tienen menos de 10 años de diagnóstico, 76 por ciento de los casos se clasificaron SIDA por conteo bajo de CD4 y fue la neurotoxoplasmosis la enfermedad marcadora de SIDA más frecuente. El esquema Zidovudina- Lamivudina- Nevirapina es el más utilizado. Conclusiones: La población VIH es mayoritaria masculina y joven con escolaridad preuniversitaria y un grupo importante sin vinculo laboral. Predomina tiempo de diagnóstico menor de 10 años, los casos con CD4 por encima de 200 células/mm3 y más de la mitad de los casos tienen indicado TARV(AU)
Introduction: Infection by AIDS has being a world and national health problem. Decentralization process of the attention of these patients make possible that every day more patients assist to secondary level hospitals to be treated. Objective: To characterize patients with AIDS infection in Boyeros municipality. Material and Methods: We were carried out a descriptive, cross-sectional study, of people with AIDS residents in Boyeros municipality up to December 31 2013. Demographic variables analyzed, were age, sex, occupation, AIDS markers illnesses, time of diagnosis, CD4 count and antiretroviral treatment. Results: The biggest number of cases are of masculine sex. Most affected age groups are 20 to 39 years old and of pre-university educational level. There are 30 percent of cases are unemployed persons. 80 percent of the cases have less than 10 years of been diagnosed, 76 percent were classified as AIDS with CD4 low count. More frequent AIDS illness was neurotoxoplasmosis. Zidovudina-Lamivudina-Nevirapina is the most antiretroviral treatment utilized. Conclusions: AIDS population in Boyeros is by majority masculine and young people. There is an important group of unemployed persons. The CD4 cells count is above 200 cells/mm3 and more than a half of cases have a suitable ARVT(AU)
Asunto(s)
Humanos , Infecciones por VIH/diagnóstico , Infecciones por VIH/epidemiología , Infecciones por VIH/terapia , Antígenos CD4/uso terapéutico , Antirretrovirales/uso terapéutico , Epidemiología Descriptiva , Estudios TransversalesRESUMEN
To determine the safety and pharmacokinetics of recombinant soluble CD4 (sCD4) administered by continuous intravenous infusion to children with symptomatic human immunodeficiency virus type 1 infection, we conducted a phase I study at the National Cancer Institute. Three dose levels of sCD4 were evaluated: 100, 300, and 1000 micrograms/kg per day. After an initial 12 weeks of treatment with sCD4 alone, dideoxyinosine at a dose of 90 mg/m2 every 8 hours was added and subjects were observed for an additional 12 weeks. Combination therapy was continued in patients in whom it was well tolerated. In addition to toxicity and pharmacokinetic monitoring, surrogate markers of antiviral activity were evaluated. Eleven children were enrolled in the study. During the 12 weeks of treatment with sCD4 alone, and during subsequent sCD4 plus dideoxyinosine combination therapy, no significant toxic reaction attributable to sCD4 or dideoxyinosine was encountered. Low-level anti-CD4 antibodies developed in two patients. Steady-state sCD4 levels increased proportionately at higher doses. The CD4 cell counts and serum p24 antigen levels did not provide evidence of antiviral activity. We conclude that sCD4 was well tolerated at doses up to 1000 micrograms/kg per day when administered by continuous intravenous infusion; however, evidence of in vivo antiviral activity was not observed in this study.